MOR 106

Drug Profile

MOR 106

Alternative Names: MOR106

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV; MorphoSys
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 19 Jul 2018 MorphoSys and Galapagos enter into an exclusive worldwide licensing agreement with Novartis for development and commercialisation of MOR 106
  • 19 Jul 2018 Novartis plans a phase I trial in Healthy volunteers and Atopic dermatitis (SC)
  • 01 Mar 2018 Phase-II clinical trials in Atopic dermatitis in Hungary (IV) (EudraCT2017-001142-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top